## Abstract An international randomized trial in Langerhans cell histiocytosis (LCH) has been initiated by the Histiocyte Society. This report reviews the rationale, design, and progress of LCHβI, which compares etoposide (VPβ16) and vinblastine in the treatment of disseminated LCH. Data on the ris
Langerhans cell histiocytosis and etoposide: Risks vs. Benefits
β Scribed by D'Angio, Giulio J.
- Book ID
- 102523606
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 308 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## SUMMARY Langerhans cell histiocytosis is a rare condition that can affect any organ of the body. Patients of all ages may present to the dermatologist and it is important to make the diagnosis as quickly as possible, because time from presentation to diagnosis is of prognostic importance in adul
Six children received etoposide as the single agent for treatment of Langerhans cell histiocytosis (LCH; histiocytosis X). Five were less than 2 years old at diagnosis. All had multiorgan involvement; one had liver and pulmonary dysfunction. Two infants also had clinical signs of immune deficiency.